Page last updated: 2024-11-02

piracetam and Cancer, Second Primary

piracetam has been researched along with Cancer, Second Primary in 1 studies

Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.

Research Excerpts

ExcerptRelevanceReference
"Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14."5.43Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016)
"Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14."1.43Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Peddi, P1
Ajit, NE1
Burton, GV1
El-Osta, H1

Other Studies

1 other study available for piracetam and Cancer, Second Primary

ArticleYear
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
    BMJ case reports, 2016, Dec-23, Volume: 2016

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; D

2016